PGRN can down-regulate the Wnt1/β-catenin signaling pathways in hyperhomocysteinemia, with various activities in diverse cell types through processes such as the regulation of the cell fate determination, the expression of the podocyte differentiation markers, as well as the permeability of the endothelial cells. This evidence concerns the gene GRN and hyperhomocysteinemia.